Should Equitable's Launch of SCS Premier Spur EQH Investors to Reassess the Firm's Risk-Reward Profile?

• In September 2025, Equitable announced the launch of Structured Capital Strategies Premier (SCS Premier), its latest registered index-linked annuity featuring enhanced upside potential, new death benefit options, and significant allocation flexibility for clients.
• The introduction of innovations like the Best Entry “do-over” feature and a -40% downside protection buffer positions SCS Premier as a differentiated retirement planning product for investors seeking market participation with tailored risk management.
• We’ll explore how these expanded investment choices and risk-mitigation features could influence Equitable’s investment narrative and long-term growth outlook.

We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Equitable Holdings Investment Narrative Recap

Equitable Holdings shareholders are typically betting on the company’s ability to drive growth through demographic tailwinds and ongoing product innovation in retirement solutions, positioning itself to benefit from rising demand among aging Americans. The launch of SCS Premier with expanded upside and downside protection is a tangible response to competitive pressure in the RILA segment, but by itself, the announcement is unlikely to materially shift the biggest near-term catalyst: sustained net inflows and asset growth from its retirement and wealth management businesses. Meanwhile, the most significant headwind, margin compression from runoff of older, higher-return RILA blocks and intensifying market competition, remains at the forefront for investors.

Among recent company developments, the acceleration of digital onboarding for Equitable’s Employee Benefits platform on August 28, 2025, stands out as highly relevant. This directly complements the SCS Premier rollout by making it easier for clients and advisors to engage with Equitable’s suite of retirement planning solutions, which supports the ongoing catalyst of expanding distribution and improving advisor productivity.

Yet, despite these advancements, investors should also be aware that should margin pressures accelerate due to competitive pricing and market saturation, the company’s...

Read the full narrative on Equitable Holdings (it's free!)

Equitable Holdings' narrative projects $18.3 billion revenue and $2.3 billion earnings by 2028. This requires 9.5% yearly revenue growth and a $1.87 billion earnings increase from $429.0 million.

Uncover how Equitable Holdings' forecasts yield a $65.27 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community member fair value estimates for Equitable Holdings range dramatically from US$7.57 to US$65.27, reflecting just two distinct viewpoints. While many see growth catalysts around expanded retirement offerings, opinions on long-term margin resilience vary greatly, explore several perspectives as you assess the outlook.

Explore 2 other fair value estimates on Equitable Holdings - why the stock might be worth as much as 30% more than the current price!

Build Your Own Equitable Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Equitable Holdings research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Equitable Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Equitable Holdings' overall financial health at a glance.

No Opportunity In Equitable Holdings?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com